Vitamin D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With but Not Without Rituximab
Vitamin D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With but Not Without Rituximab
复制标题
DOI：
10.1200/jco.2013.53.4537
复制
发表时间：
2014-10-10
影响因子：
45.3
通讯作者：
Pfreundschuh, Michael
中科院分区：
文献类型：
--
作者：
Bittenbring, Joerg Thomas;Neumann, Frank;Pfreundschuh, Michael
PurposeTo investigate the impact and mechanisms of vitamin D deficiency (VDD) on the outcome of elderly patients with diffuse large B-cell lymphoma (DLBCL).Patients and MethodsThree hundred fifty-nine pretreatment 25-hydroxyvitamin D3 (25[OH] D3) serum levels from the RICOVER-60 study (Six Versus Eight Cycles of Biweekly CHOP-14 With or Without Rituximab in Elderly Patients With Aggressive CD20+ B-Cell Lymphomas) and 63 from the RICOVER-noRTh study (an amendment to the RICOVER-60 study in which patients received six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone administered at an interval of 2 weeks plus two cycles of rituximab [R-CHOP-14], but without radiotherapy) were determined by chemoluminescent immunoassay. Rituximab-mediated cellular cytotoxicity (RMCC) was assessed by lactate dehydrogenase release assay of CD20(+) Daudi cells.ResultsRICOVER-60 patients with VDD (
